Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.

Szczegóły

Tytuł:: Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.
Autorzy:: Arroyo-Andrés J; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
Agud-Dios M; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
Rubio-Muniz CA; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
Vico-Alonso C; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
Cortijo-Cascajares S; Pharmacy Department, 12 de Octubre University Hospital, Madrid, Spain.
Ortiz-Romero PL; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
Źródło:: International journal of dermatology [Int J Dermatol] 2022 Jul; Vol. 61 (7), pp. e267-e269. Date of Electronic Publication: 2021 Aug 07.
Typ publikacji:: Case Reports; Letter; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: Oxford : Blackwell Science
Original Publication: Philadelphia, Lippincott.
MeSH Terms:: Brentuximab Vedotin*/therapeutic use
Immunoconjugates*/therapeutic use
Lymphoma, Large-Cell, Anaplastic*/diagnosis
Lymphoma, Large-Cell, Anaplastic*/drug therapy
Lymphoma, Large-Cell, Anaplastic*/pathology
Antineoplastic Agents, Immunological/therapeutic use ; Humans ; Ki-1 Antigen
References:: Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.
Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. Blood 2011; 118: 4024-4035.
Vonderheid E, Sajjadian A, Kadin M. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-481.
Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555-566.
Hoffmann J, Soliman M, Koch J, et al. Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin. J Eur Acad Dermatol Venereol 2020; 34: e626-e628.
Grant Information:: PI17/00957 FIS
Substance Nomenclature:: 0 (Antineoplastic Agents, Immunological)
0 (Immunoconjugates)
0 (Ki-1 Antigen)
7XL5ISS668 (Brentuximab Vedotin)
Entry Date(s):: Date Created: 20210807 Date Completed: 20220616 Latest Revision: 20220629
Update Code:: 20240105
DOI:: 10.1111/ijd.15834
PMID:: 34363613
: Raport

Full Text Finder

Informacja